His research focuses on improving outcomes for children diagnosed with myeloid malignancies, particularly those with juvenile myelomonocytic leukemia (JMML), an aggressive hematologic malignancy of childhood. As his primary clinical focus, Dr. Stieglitz is study chair for ADVL1512, a phase II clinical trial sponsored by the Children's Oncology Group (COG) that will evaluate the safety of trametinib in children with relapsed JMML. This trial has recently been approved by the COG and is expected to enroll patients by the end of 2017. His primary laboratory focus is elucidating the mechanism of mutant SETBP1-mediated leukemogenesis, which is associated with the most aggressive form of JMML and is the subject of a K08 award.